Response to pre-radiation chemotherapy as a predictor of survival in patients with newly diagnosed malignant astrocytoma: A north central cancer treatment group (NCCTG) study

被引：0
|
作者：
Jaeckle, K
Ballman, K
O'Fallon, J
Scheithauer, B
Giannini, C
Moynihan, T
Buckner, J
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] Mayo Clin, Rochester, MN USA
来源：
NEURO-ONCOLOGY | 2004年 / 6卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：376 / 376
页数：1
相关论文
共 50 条
  • [1] IS RESPONSE A MEANINGFUL SURROGATE FOR SURVIVAL FNDPOINTS IN CLINICAL TRIALS INVOLVING NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA PATIENTS? A NORTH CENTRAL CANCER TREATMENT GROUP (NCCTG) STUDY
    Jaeckle, Kurt
    Xu, Wenting
    Ballaman, Karla
    Flynn, Patrick
    Buchner, Jan
    NEURO-ONCOLOGY, 2008, 10 (05) : 842 - 843
  • [2] Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials
    Jaeckle, K. A.
    Wu, W.
    Kosel, M.
    Flynn, P. J.
    Buckner, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Pre-radiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: A retrospective analysis
    Kim, C.
    Han, J.
    Park, C.
    Lee, S.
    Kim, D.
    Paek, S.
    Kim, D.
    Heo, D.
    Kim, I.
    Jung, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] PHASE II EVALUATION OF GEFITINIB IN PATIENTS WITH NEWLY DIAGNOSED GRADE 4 ASTROCYTOMA: MAYO/NORTH CENTRAL CANCER TREATMENT GROUP STUDY N0074
    Uhm, Joon H.
    Ballman, Karla V.
    Wu, Wenting
    Giannini, Caterina
    Krauss, J. C.
    Buckner, Jan C.
    James, C. D.
    Scheithauer, Bernd W.
    Behrens, Robert J.
    Flynn, Patrick J.
    Schaefer, Paul L.
    Dakhill, Shaker R.
    Jaeckle, Kurt A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (02): : 347 - 353
  • [5] Relationship of administration of enzyme-inducing anticonvulsants (EIAC) to survival in patients with glioblastoma: A north central cancer treatment group (NCCTG) study
    Jaeckle, K
    Ballman, K
    Uhm, J
    O'Fallon, J
    Schomberg, P
    Scheithauer, B
    Giannini, C
    Flynn, P
    Buckner, J
    NEURO-ONCOLOGY, 2004, 6 (04) : 376 - 376
  • [6] NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial.
    Ma, Daniel
    Galanis, Evanthia
    Schiff, David
    Wu, Wenting
    Peller, Patrick J.
    Giannini, Caterina
    Brown, Paul D.
    Uhm, Joon H.
    McGraw, Steven
    Jaeckle, Kurt A.
    Flynn, Patrick J.
    Buckner, Jan C.
    Sarkaria, Jann Nagina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study
    Alberts, SR
    Townley, PM
    Goldberg, RM
    Cha, SS
    Moore, DF
    Krook, JE
    Pitot, HC
    Fitch, TR
    Wiesenfeld, M
    Mailliard, JA
    Sargent, DJ
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 553 - 557
  • [8] Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors
    Grossman, Stuart A.
    Ellsworth, Susannah
    Campian, Jian
    Wild, Aaron T.
    Herman, Joseph M.
    Laheru, Dan
    Brock, Malcolm
    Balmanoukian, Ani
    Ye, Xiaobu
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (10): : 1225 - 1231
  • [9] RESULTS OF RANDOMIZED CHEMOTHERAPY TRIALS FOR NEWLY DIAGNOSED MEDULLOBLASTOMA, MALIGNANT ASTROCYTOMA, AND BRAIN-STEM GLIOMA FROM THE CHILDRENS CANCER STUDY-GROUP
    ALLEN, J
    ERTEL, I
    EVANS, A
    JENKIN, D
    SPOSTO, R
    HAMMOND, D
    ANNALS OF NEUROLOGY, 1984, 16 (03) : 403 - 403
  • [10] Comparison of outcome of patients with newly diagnosed and recurrent gliomas treated on north central cancer treatment group (NCCTG) phase II and III trials within the community as compared to an academic medical center
    Jaeckle, K. A.
    Furth, A. F.
    Wu, W.
    Ballman, K. V.
    Flynn, P. J.
    Brown, P. D.
    Galanis, E.
    Buckner, J. C.
    NEURO-ONCOLOGY, 2006, 8 (04) : 406 - 407
12345